Visus Therapeutics completed enrollment in a pivotal phase 3 trial investigating Brimochol PF for the treatment of presbyopia.
The double-masked, randomized, multicenter BRIO-I trial will evaluate the safety and efficacy of Brimochol PF (carbachol and brimonidine tartrate) in emmetropic phakic and pseudophakic presbyopic participants, according to a press release. The preservative-free ophthalmic solution works by reducing the size of the pupil to sharpen vision by allowing only the light rays focused on the retina to enter the eye.
“BRIO-I is a safety and efficacy study whose primary